The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients

Xingnan Li; Elizabeth J. Ampleford; Timothy D. Howard; Wendy C. Moore; Huashi Li; William W. Busse; Mario Castro; Serpil C. Erzurum; Anne M. Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N. Jarjour; W. Gerald Teague; Sally E. Wenzel; Gregory A. Hawkins; Eugene R. Bleecker; Deborah A. Meyers

doi:10.1016/j.jaci.2011.09.040

The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients

Xingnan Li, Elizabeth J. Ampleford, Timothy D. Howard, Wendy C. Moore, Huashi Li, William W. Busse, Mario Castro, Serpil C. Erzurum, Anne M. Fitzpatrick, Benjamin Gaston, Elliot Israel, Nizar N. Jarjour, W. Gerald Teague, Sally E. Wenzel, Gregory A. Hawkins, Eugene R. Bleecker, Deborah A. Meyers

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Original language	English
Pages (from-to)	575-578.e9
Journal	Journal of Allergy and Clinical Immunology
Volume	129
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2011.09.040
State	Published - Feb 2012
Externally published	Yes

Access to Document

10.1016/j.jaci.2011.09.040

Cite this

Li, X., Ampleford, E. J., Howard, T. D., Moore, W. C., Li, H., Busse, W. W., Castro, M., Erzurum, S. C., Fitzpatrick, A. M., Gaston, B., Israel, E., Jarjour, N. N., Teague, W. G., Wenzel, S. E., Hawkins, G. A., Bleecker, E. R., & Meyers, D. A. (2012). The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients. Journal of Allergy and Clinical Immunology, 129(2), 575-578.e9. https://doi.org/10.1016/j.jaci.2011.09.040

@article{fa6bae4459fa4e23a9615e1b7a5c3d42,

title = "The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients",

author = "Xingnan Li and Ampleford, {Elizabeth J.} and Howard, {Timothy D.} and Moore, {Wendy C.} and Huashi Li and Busse, {William W.} and Mario Castro and Erzurum, {Serpil C.} and Fitzpatrick, {Anne M.} and Benjamin Gaston and Elliot Israel and Jarjour, {Nizar N.} and Teague, {W. Gerald} and Wenzel, {Sally E.} and Hawkins, {Gregory A.} and Bleecker, {Eugene R.} and Meyers, {Deborah A.}",

note = "Funding Information: Disclosure of potential conflict of interest: W. W. Busse is on the advisory board for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the NIH/National Heart, Lung, and Blood Institute (NHLBI) . M. Castro is a consultant and speaker for Asthmatx; is on the advisory board of and speaker for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received grants through his institution from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, Novartis, the NIH , and GlaxoSmithKline; has received royalties from Elsevier; and has received research support from the NIH . S. C. Erzurum has received research support from Asthmatx . B. Gaston is on the advisory board of Respiratory Research, Inc, and Galleon Pharmaceuticals and has received research support from the NIH . N. N. Jarjour has received research support from GlaxoSmithKline, Merck, and Genentech and has provided legal consultation services/expert witness testimony for Genentech and Asthmatx. G. A. Hawkins has received research support from the NIH . The rest of the authors declare that they no relevant conflicts of interest. Funding Information: SARP centers were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762 . Genetic studies for SARP and CSGA were funded by NIH grant HL87665 . The clinical TENOR study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation , and the genetic studies were funded by NIH grants HL76285 and HL87665 . ",

year = "2012",

month = feb,

doi = "10.1016/j.jaci.2011.09.040",

language = "English",

volume = "129",

pages = "575--578.e9",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "2",

}

Li, X, Ampleford, EJ, Howard, TD, Moore, WC, Li, H, Busse, WW, Castro, M, Erzurum, SC, Fitzpatrick, AM, Gaston, B, Israel, E, Jarjour, NN, Teague, WG, Wenzel, SE, Hawkins, GA, Bleecker, ER & Meyers, DA 2012, 'The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients', Journal of Allergy and Clinical Immunology, vol. 129, no. 2, pp. 575-578.e9. https://doi.org/10.1016/j.jaci.2011.09.040

TY - JOUR

T1 - The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients

AU - Li, Xingnan

AU - Ampleford, Elizabeth J.

AU - Howard, Timothy D.

AU - Moore, Wendy C.

AU - Li, Huashi

AU - Busse, William W.

AU - Castro, Mario

AU - Erzurum, Serpil C.

AU - Fitzpatrick, Anne M.

AU - Gaston, Benjamin

AU - Israel, Elliot

AU - Jarjour, Nizar N.

AU - Teague, W. Gerald

AU - Wenzel, Sally E.

AU - Hawkins, Gregory A.

AU - Bleecker, Eugene R.

AU - Meyers, Deborah A.

N1 - Funding Information: Disclosure of potential conflict of interest: W. W. Busse is on the advisory board for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the NIH/National Heart, Lung, and Blood Institute (NHLBI) . M. Castro is a consultant and speaker for Asthmatx; is on the advisory board of and speaker for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received grants through his institution from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, Novartis, the NIH , and GlaxoSmithKline; has received royalties from Elsevier; and has received research support from the NIH . S. C. Erzurum has received research support from Asthmatx . B. Gaston is on the advisory board of Respiratory Research, Inc, and Galleon Pharmaceuticals and has received research support from the NIH . N. N. Jarjour has received research support from GlaxoSmithKline, Merck, and Genentech and has provided legal consultation services/expert witness testimony for Genentech and Asthmatx. G. A. Hawkins has received research support from the NIH . The rest of the authors declare that they no relevant conflicts of interest. Funding Information: SARP centers were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762 . Genetic studies for SARP and CSGA were funded by NIH grant HL87665 . The clinical TENOR study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation , and the genetic studies were funded by NIH grants HL76285 and HL87665 .

PY - 2012/2

Y1 - 2012/2

UR - http://www.scopus.com/inward/record.url?scp=84856459633&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2011.09.040

DO - 10.1016/j.jaci.2011.09.040

M3 - Article

C2 - 22070912

AN - SCOPUS:84856459633

SN - 0091-6749

VL - 129

SP - 575-578.e9

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -

The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients

Access to Document

Other files and links

Cite this